Cytogenix (fka CYGX)

[percywhit]

Here is an example........

I posted this Press Release before it was released to the public. Goback and look at the post in this time span and you can see. Someone asked me where I found this PR and I said it came to me in a dream I believe.

Posted by: percywhit
In reply to: None Date:11/13/2003 6:12:02 AM
Post #of 14663

*********************NEWS*************************************

CytoGenix Announces Acceptance for Publication by Prestigious Scientific Journal, Data Shows the Effectiveness of its Novel Anti-bacterial Agent

Houston, TX (November 13, 2003) CytoGenix, Inc. (CYGX:OTCBB) announced Thursday that results of research conducted by Dr. Yin Chen, Vice President of R & D and Dr. Xin Xing Tan, Senior Scientist of CytoGenix, will be published in an upcoming issue of Biochemistry a respected research journal. This study demonstrates that the company's proprietary ssDNA technology is effective in preventing the growth of bacteria such as the strains that cause sepsis and other potentially fatal diseases.

Biochemistry, an American Chemical Society journal is dedicated to "publishing the results of original research that contribute significantly to the understanding of the mechanism of biological phenomena in terms of molecular structure and/or function. Biochemistry investigates the rapidly changing arena where chemistry, biochemistry and molecular and cell biology interrelate." Dr. Chen and Dr. Tan's paper is titled "DNA Enzyme Generated by a Novel Single-Stranded DNA _Expression Vector Inhibits _Expression of the Essential Bacterial Cell Division Gene ftsZ"will be published in the next few weeks.

"This is the fourth scientific paper from the Company's laboratory published this year and the seventh in the past two years, a very significant achievement for any research group whether academic, government or industry. We appreciate the scientific community's recognition of the merit of this work." states Dr. Malcolm Skolnick, Chairman/CEO. "In an era of hundred million dollar research budgets, we continue to prove that valuable science can be produced with very modest means." adds Dr. Skolnick.

CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA _expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a US patent for its core DNA _expression technology and has 40 international or US pending patent applications.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

Contact: Communications Director - Juan Ferreira, [phone].